Healthcare / BiotechnologyShenzhen
$8.32
-0.31 (-3.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $99.0M · quality 40.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.1B
P/E
277.3x
↑EV/EBITDA
25.3x
↑ROE
1.1%
↑Gross Margin
28.6%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.1%
FCF CAGR
—
FCF margin
11.3%
FCF / Net income
9.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.13B · net income $13.4M · FCF $128.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.13B | $1.13B | $970.2M | $1.14B | $1.33B |
| Net Income | $13.4M | $13.4M | $-226.5M | $-916.8M | $362.6M |
| EBITDA | $149.2M | $149.2M | $-73.8M | $-768.8M | $988.0M |
| EPS | 0.03 | 0.03 | -0.45 | -1.84 | 0.73 |
| Gross Margin | 28.6% | 28.6% | 21.8% | 25.9% | 25.4% |
| Operating Margin | 3.4% | 3.4% | -4.4% | -3.3% | -4.6% |
| Net Margin | 1.2% | 1.2% | -23.3% | -80.5% | 27.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.42 | 0.44 | 0.41 |
| Current Ratio | 2.15 | 2.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $128.0M | $128.0M | $99.0M | $-50.3M | $-73.7M |
| Returns | |||||
| ROE | 1.1% | 1.1% | -18.7% | -63.8% | 15.5% |
| Valuation | |||||
| P/E | 277.33 | 277.33 | — | — | 14.48 |
| EV/EBITDA | 25.32 | 25.32 | — | — | 5.52 |
| P/B | 2.92 | 2.92 | 2.48 | 2.54 | 2.24 |
| Growth & Yield | |||||
| Revenue Growth | 17.0% | 17.0% | -14.8% | -14.2% | — |
| EPS Growth | 106.7% | 106.7% | 75.5% | -352.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
190.9%
EPS terminal req.
$0.74
Spread vs growth
-84.2%
5Y implied EPS CAGR
97.1%
EPS terminal req.
$0.89
Spread vs growth
9.5%
10Y implied EPS CAGR
47.3%
EPS terminal req.
$1.44
Spread vs growth
59.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.45 → 0.03
Residual
+27.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.